Andrew Hirschberg

Andrew ("Andy") Hirschberg is a career healthcare investment banker with roughly three to four decades advising clients on mergers, acquisitions, financings, and in/out-licensing transactions, chiefly in specialty pharmaceuticals, medical devices, and consumer products. He is currently Head of Investment Banking at Triad Healthcare Partners, a division of the New York broker-dealer Triad Securities Corp., which he helped form in February 2014 to provide global investment-banking services to pharmaceutical and medical-device companies. Over his career he reports having completed more than 100 transactions across specialties including dermatology, gastroenterology, pediatrics, and nephrology, with an aggregate value exceeding $5 billion.

Before Triad, Hirschberg worked as an investment banker at Roberts Mitani (later rebranded RM Global), a life-science-focused investment bank and strategic advisory firm covering biopharma, biotech, medical devices, consumer/digital health, and diagnostics — the firm that also ran the RMGP BioPharma Fund and Global BioAccess Fund. The stub's Roberts Mitani email and New York phone number trace to this earlier chapter of his career. At Triad he partners with Mark Palmer (a former business-development leader at Braintree Laboratories and Medicis Pharmaceutical) on deal sourcing, negotiation, and execution.

According to the University of Chicago's Polsky Center for Entrepreneurship and Innovation, Hirschberg graduated from Colgate University (1982), earned a Master's in Accounting from NYU's Stern School of Business, and holds an MBA from the University of Chicago Booth School of Business (Class of 1988). The same profile notes that beyond his advisory work in specialty pharma and consumer products, he "has also been an investor in, and advisor to, numerous start-up and early-stage companies" — the basis for his classification as an angel/seed investor.

He is a registered securities professional; FINRA's BrokerCheck lists Andrew Jay Hirschberg (CRD #5935160) as a broker at Triad Securities Corp.

• Domain-first, healthcare-centric: His entire track record sits in specialty pharma, medical devices, biopharma, diagnostics, and consumer/digital health — he backs and advises companies in areas he knows deeply, not generalist tech.
• Angel checks into early-stage companies: Personally described as "an investor in, and advisor to, numerous start-up and early-stage companies" (Polsky Center), consistent with the seed-stage label in the stub.
• Advisor-investor model: He tends to combine capital with hands-on strategic and transactional guidance (licensing, M&A, financing), reflecting his investment-banking background rather than passive check-writing.
• Cross-border comfort: His firm history includes structuring deals with Japanese strategic and financial partners (e.g., IASU Co. and Cosmotec Co. in the Pinyons Medical financing), suggesting openness to international strategics as acquirers or co-investors.